

Marwan Bukhari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9245845/publications.pdf>

Version: 2024-02-01

140
papers

3,911
citations

230014

27
h-index

145109

60
g-index

142
all docs

142
docs citations

142
times ranked

6492
citing authors

#	ARTICLE	IF	CITATIONS
1	Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkab089.	0.3	2
2	Retrospective Analysis of Factors Associated with Fracture in 714 Patients with Polymyalgia Rheumatica. <i>International Journal of Rheumatology</i> , 2022, 2022, 1-6.	0.9	1
3	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Reply. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac011.	0.3	0
4	Cluster analysis demonstrates co-existing sites of fragility fracture and associated comorbidities. <i>Osteoporosis International</i> , 2022, , 1.	1.3	0
5	Safety of jakinibs: lessons from ORAL Surveillance. <i>Rheumatology</i> , 2022, 61, 4223-4225.	0.9	1
6	COVID-19 and mortality in rare rheumatic diseases, a warning bell?. <i>Rheumatology</i> , 2021, 60, 1580-1581.	0.9	2
7	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. <i>Rheumatology</i> , 2021, 60, 2037-2039.	0.9	1
8	P101â€¦Identifying factors that predict fracture risk in polymyalgia rheumatica. <i>Rheumatology</i> , 2021, 60, .	0.9	0
9	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 1637-1645.	6.3	1,374
10	Empathic communication during a pandemic: How can we minimize the deficit?. <i>Rheumatology</i> , 2021, 60, SI1-SI2.	0.9	0
11	Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. <i>Rheumatology</i> , 2021, 60, 4972-4981.	0.9	7
12	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. <i>Journal of Rheumatology</i> , 2021, 48, 1201-1204.	1.0	5
13	The role of 14-3-3 Î· as a biomarker in rheumatoid arthritis. <i>Rheumatology and Immunology Research</i> , 2021, 2, 87-90.	0.2	0
14	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18
15	Colchicine and the heart: old friends, old foes. <i>Rheumatology</i> , 2021, 60, 2035-2036.	0.9	3
16	A deeper dive into rare autoimmune diseases, death and COVID-19 in the first wave of the pandemic. <i>Rheumatology</i> , 2021, , .	0.9	0
17	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , 2020, 59, 213-223.	0.9	22
18	The relationship between citations, downloads and alternative metrics in rheumatology publications: a bibliometric study. <i>Rheumatology</i> , 2020, 59, 277-280.	0.9	21

#	ARTICLE	IF	CITATIONS
19	How rheumatologists assess disability in the current era needs an overhaul: focus on the Health Assessment Questionnaire. <i>Rheumatology</i> , 2020, 59, 267-268.	0.9	4
20	The benefits and challenges of providing patient education digitally. <i>Rheumatology</i> , 2020, 59, 3591-3592.	0.9	7
21	Real-life experience of tocilizumab use in COVID-19 patients. <i>Rheumatology</i> , 2020, 59, 2163-2166.	0.9	5
22	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
23	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
24	Better is possible. <i>Rheumatology</i> , 2019, 58, 741-742.	0.9	0
25	Are we failing patients in our assessment of treatment failure?. <i>Rheumatology</i> , 2019, 58, 561-562.	0.9	4
26	The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. <i>Rheumatology</i> , 2019, 58, e3-e42.	0.9	96
27	The price of good health care. <i>Rheumatology</i> , 2019, 58, 931-932.	0.9	1
28	The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritisâ€”Executive summary. <i>Rheumatology</i> , 2019, 58, 220-226.	0.9	38
29	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factorâ€”treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	0.9	26
30	A Multicenter, Randomized, Placeboâ€”Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	2.9	77
31	An atypical presentation of subacute cutaneous lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 2142-2142.	0.9	0
32	Predictors of fragility fracture and low bone mineral density in patients with a history of parental fracture. <i>Osteoporosis and Sarcopenia</i> , 2019, 5, 6-10.	0.7	7
33	Do we need to perform MRI of the whole spine in addition to MRI of the sacroiliac joints in suspected spondyloarthropathy?. <i>Clinical Radiology</i> , 2019, 74, 409.e1-409.e6.	0.5	4
34	Symptomatic patients with P369Sâ€”R408Q mutations: familial Mediterranean fever or mixed auto-inflammatory syndrome?. <i>BMJ Case Reports</i> , 2019, 12, e228858.	0.2	1
35	FRI0503â€”...USING BONE MINERAL DENSITY VERSUS THE RATIO OF BODY MASS INDEX TO BONE MINERAL DENSITY TO PREDICT FRACTURE RISK IN HYPERTHYROIDISM. , 2019, , .		0
36	FRI0482â€”...RISK FACTORS FOR FRAGILITY FRACTURE IN PATIENTS WHO SMOKE: AN OBSERVATIONAL STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	FRIO638â€¦LUMBAR SPINE BONE MASS DENSITY AS A PREDICTOR OF FRACTURES IN PATIENTS WITH COELIAC DISEASE: AN OBSERVATIONAL STUDY. , 2019, , .		0
38	AB0483â€¦A SYSTEMATIC LITERATURE REVIEW ON THE USE OF BIOLOGICS IN SJÅ–GRENâ€™S SYNDROME. , 2019, , .		0
39	FRIO081â€¦WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. , 2019, , .		1
40	SAT0246â€¦USING BONE MINERAL DENSITY VERSUS THE RATIO OF BODY MASS INDEX TO BONE MINERAL DENSITY TO PREDICT FRACTURE RISK IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
41	Acroosteolysis in a patient with systemic lupus erythematosus/mixed connective tissue disease. <i>Rheumatology</i> , 2019, 58, 426-426.	0.9	2
42	Hello from the new Editor-in-Chief. <i>Rheumatology</i> , 2019, 58, 1-2.	0.9	14
43	Comment on: Should Rheumatology be a core discipline of a chronic pain multi-disciplinary team?: reply. <i>Rheumatology</i> , 2019, 58, 185-186.	0.9	0
44	Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms. <i>Rheumatology</i> , 2019, 58, 375-376.	0.9	10
45	Is remission achievable in most patients with rheumatoid arthritis? Results suggest not. <i>Rheumatology</i> , 2019, 58, 187-188.	0.9	4
46	Predictors of fracture risk in patients with systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1547-1551.	0.8	7
47	Prevalence of Pagetâ€™s disease of bone in Lancaster: time for an update. <i>Rheumatology</i> , 2018, 57, 931-932.	0.9	11
48	Twitter, #alternativefacts, careless whispers and Rheumatology. <i>Rheumatology</i> , 2018, 57, 773-774.	0.9	7
49	Should Rheumatology be a core discipline of a chronic pain multi-disciplinary team?. <i>Rheumatology</i> , 2018, 57, 949-950.	0.9	2
50	Building the future of rheumatology: the role of national and international networks. <i>Rheumatology</i> , 2018, 57, 405-407.	0.9	1
51	Recent pharmacological advances in the management of gout. <i>Rheumatology</i> , 2018, 57, 951-958.	0.9	13
52	AB0302â€¦The role of the biomarker 14â€“3â€“3 eta in rheumatoid arthritis: a review. , 2018, , .		1
53	THU0699â€¦Predictors of fracture and low bone mineral density in patients with history of parental fracture. , 2018, , .		0
54	AB0375â€¦A systematic literature review of omega 3 in the treatment of rheumatoid arthritis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
55	Evidence-based practice is the gold standard and should be adhered to at all times”or should it?. Rheumatology, 2018, 57, 2067-2069.	0.9	2
56	AB0267”Baseline predictors of response to methotrexate in early rheumatoid arthritis. , 2018, , .		1
57	AB0213”Correlation between components of the das28 score and health assessment questionnaire in early rheumatoid arthritis. , 2018, , .		0
58	AB0996”Bone mineral density at different sites as a predictor of rib fractures: a case-control study. , 2018, , .		0
59	SAT0705”Association between fracture sites in patients with a history of parental fracture. , 2018, , .		0
60	AB1324”Studying the relationship between body mass index, bmi, and bone mineral density, bmd, of lumbar vertebrae and femoral neck. , 2018, , .		1
61	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2017, 76, 497-503.	0.5	88
62	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2017, 72, 764-771.	0.5	63
63	New use for tocilizumab in giant cell arteritis. Rheumatology, 2017, 56, kew489.	0.9	0
64	Effects of superoxide dismutase on chondrocytes in osteoarthropathy of alkaptonuria. Osteoarthritis and Cartilage, 2017, 25, S148-S149.	0.6	0
65	Nitisinone therapy shows beneficial effects on the chondrocytes and extracellular matrix in the osteoarthropathy of alkaptonuria. Osteoarthritis and Cartilage, 2017, 25, S152.	0.6	1
66	FRI0543”Which factors can help predict fragility fractures in patients diagnosed with inflammatory bowel disease? a case-control study. , 2017, , .		0
67	FRI0560”Predictors of fractures in female patients with anorexia. , 2017, , .		0
68	FRI0565”Fragility fractures in patients on depo-provera are not associated with usual risk factors for fracture. , 2017, , .		0
69	FRI0538”Evaluation of factors that increase fracture risk in breast cancer. , 2017, , .		0
70	AB0260”The predictors of fragility fractures in patients on aromatase inhibitors: an observational study. , 2017, , .		0
71	AB0788”Predictors of Fractures in Excessive Consumption of Alcohol: An Observational Study:. Annals of the Rheumatic Diseases, 2016, 75, 1173.3-1173.	0.5	0
72	AB0708”Delay To Diagnosis in Ankylosing Spondylitis: A Local Perspective. Annals of the Rheumatic Diseases, 2016, 75, 1146.3-1147.	0.5	3

#	ARTICLE	IF	CITATIONS
73	THU0068â€¦..Absolute Monocyte Counts Are Associated with Adverse EULAR Response after 6 Months of Treatment with A Biologic Agent for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 203.1-203.	0.5	0
74	Osteoanabolic therapy: a valid option to reduce refracture risk after vertebral augmentation procedures?. <i>Osteoporosis International</i> , 2016, 27, 3387-3388.	1.3	2
75	2015 EULARâ€™ACR recommendations for polymyalgia rheumatica: the message and next steps. <i>Rheumatology</i> , 2016, 55, 955-956.	0.9	1
76	THU0462â€¦..The Predictors of Fracture in Patients with Coeliac Disease: An Observational Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 359.3-359.	0.5	0
77	FRI0383â€¦..Predictors of Fragility Fractures in Patients with Polymyalgia Rheumatica on Steroids: An Observational Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 573.1-573.	0.5	0
78	AB0097â€¦..The Presence of Staphylococcal Toxins in The Urine of Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 930.1-930.	0.5	3
79	THU0482â€¦..Predictors of Fractures in Patients with Untreated Early Menopause: An Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 366.1-366.	0.5	0
80	THU0101â€¦..The Predictors of Fragility Fracture in Patients with Rheumatoid Arthritis: An Observational Study:. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 215.3-216.	0.5	0
81	AB0575â€¦..Steroid Use Is Protective of Osteoporosis in Polymyalgia Rheumatica Patients: A Case-Control Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1101.2-1101.	0.5	1
82	AB0796â€¦..The Predictors of Fracture in Patients with Hyperparathyroidism: An Observational Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1176.1-1176.	0.5	0
83	Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2080-2086.	0.5	61
84	A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria. <i>Clinical Rheumatology</i> , 2016, 35, 1849-1856.	1.0	10
85	Have we had a paradigm change in the treatment of rheumatoid arthritis after the American Congress of Rheumatology 2015?: Table 1. <i>Rheumatology</i> , 2016, 55, 1531-1533.	0.9	1
86	Use of biologics in SLE: a review of the evidence from a clinical perspective. <i>Rheumatology</i> , 2016, 55, 775-779.	0.9	10
87	Osteoarticular cells tolerate short-term exposure to nitisinoneâ€™implications in alkaptonuria. <i>Clinical Rheumatology</i> , 2016, 35, 513-516.	1.0	4
88	Increasing body fat mass reverses bone loss in osteopenia as detected by dual-energy X-ray absorptiometry scans. <i>European Journal of Rheumatology</i> , 2016, 3, 1-4.	1.3	3
89	PROMs vs. PREMs (Patient-Reported Experience Measures). , 2016, , 405-417.		1
90	FRI0285â€¦..The Effect of Steroids on Fracture, Adjusting for Bone Mineral Density. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 527.4-528.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Development and Validation of a Patient Reported Experience Measure (PREM) for Patients with Rheumatoid Arthritis (RA) and other Rheumatic Conditions. <i>Current Rheumatology Reviews</i> , 2015, 11, 1-7.	0.4	21
92	E22.â€fA Case of Rhabdomyolysis Induced by Febuxostat Therapy in a Patient with Hyperuricaemia and Chronic Renal Transplant Dysfunction. <i>Rheumatology</i> , 2015, , .	0.9	1
93	FRI0303â€…The Effect of Secondary Amenorrhoea on Bone Mineral Density. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 534.1-534.	0.5	0
94	SAT0289â€…Predictors of Fragility Humeral Fractures: An Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 763.1-763.	0.5	0
95	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.5	162
96	Clinical Utility of Random Antiâ€“Tumor Necrosis Factor Drugâ€“Level Testing and Measurement of Antidrug Antibodies on the Longâ€“Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
97	FRI0199â€…Does Lower Bone Mineral Density in A Single Hip PREDICT Fracture Better than Average Bone Mineral Density across Both Hips?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 454.2-455.	0.5	0
98	198.â€fVery High Body Mass Index is Associated with Osteoporosis. <i>Rheumatology</i> , 2014, 53, i133-i133.	0.9	0
99	AB0928â€…Do Osteoarthritic Cytokines Accelerate the Development of Ochronotic Arthropathy?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1107.2-1107.	0.5	0
100	A role for interleukins in the rapid progression of osteoarthritis in alkaptonuria. <i>Osteoarthritis and Cartilage</i> , 2014, 22, S61.	0.6	0
101	The prevalence of osteoporosis in an older population with very high body mass index: evidence for an association. <i>International Journal of Clinical Practice</i> , 2014, 68, 771-774.	0.8	11
102	SAT0272â€…The Use of Rituximab in Anca-Associated Vasculitides: Systematic Review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 691.2-692.	0.5	0
103	FRI0063â€…Changes in Bone Mass over Time in Subjects with Rheumatoid Arthritis: an Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 404.2-404.	0.5	0
104	SAT0474â€…Predictors of Bone Loss in Men Treated with Androgen Deprivation Therapy for Prostate Cancer: an Observational Study: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 765.1-765.	0.5	0
105	SAT0473â€…Predictive Factors of Longitudinal Bone Loss in Patients Treated with Aromatase Inhibitors for Breast Cancer. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 764.3-765.	0.5	0
106	SAT0472â€…The Effect of Aromatase Inhibitors on Different Sites of the Human Skeleton â€“ an Observational Case-Control Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 764.2-764.	0.5	0
107	OP0292â€…The Diagnosis of Osteoporosis Using BMD and T Score Measurements at Specific Skeletal Sites. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 172.2-172.	0.5	2
108	Alkaptonuria. <i>Rare Diseases (Austin, Tex)</i> , 2013, 1, e27475.	1.8	82

#	ARTICLE	IF	CITATIONS
109	SAT0364â€¦Are differences of hip shape responsible for increased femoral neck fracture risk in post-menopausal women?.. Annals of the Rheumatic Diseases, 2013, 71, 595.2-595.	0.5	0
110	SAT0344â€¦Does proximal femur shape contribute to femoral neck fracture risk in osteoporotic individuals?.. Annals of the Rheumatic Diseases, 2013, 71, 588.3-589.	0.5	0
111	Drug-induced rheumatic diseases. Current Opinion in Rheumatology, 2012, 24, 182-186.	2.0	12
112	Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Research and Therapy, 2012, 14, R109.	1.6	18
113	Isolated lower limb medium-vessel vasculitis: a new entity?. BMJ Case Reports, 2011, 2011, bcr0220113872-bcr0220113872.	0.2	1
114	A survey of new to follow-up ratios in rheumatology outpatients departments. Clinical Medicine, 2011, 11, 99.2-100.	0.8	0
115	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology, 2011, 50, 2311-2313.	0.9	42
116	Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis. Journal of Rheumatology, 2011, 38, 429-433.	1.0	2
117	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology, 2010, 49, 1197-1199.	0.9	49
118	Orthopaedics and Rehabilitation [84-85]: 84. A Comparison of Patients Referred after Fractures of the Forearm and Fractures of the Spine and HIP. Rheumatology, 2010, 49, i64-i65.	0.9	0
119	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology, 2010, 49, 2217-2219.	0.9	187
120	The National Osteoporosis Guideline Group's new guidelines: what is new?. Rheumatology, 2009, 48, 327-329.	0.9	9
121	Comment on: NICE guidance does not tally with clinical practice--a district general experience: reply. Rheumatology, 2008, 47, 1736-1736.	0.9	0
122	Assessment of the impact of new UK guidelines on the management of aromatase inhibitor-associated bone loss. Rheumatology, 2008, 48, 197-198.	0.9	1
123	Is it ever appropriate to discharge patients with rheumatoid arthritis?. Rheumatology, 2007, 46, 1631-1633.	0.9	6
124	NICE guidance does not tally with clinical practice--a district general experience. Rheumatology, 2007, 47, 222-223.	0.9	1
125	Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Annals of the Rheumatic Diseases, 2007, 66, 389-393.	0.5	36
126	The performance of anti-â€œcyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis and Rheumatism, 2007, 56, 2929-2935.	6.7	84

#	ARTICLE	IF	CITATIONS
127	The sesamoid index in psoriatic arthropathy. <i>Skeletal Radiology</i> , 2005, 34, 217-220.	1.2	13
128	Referrals to hospital-based rheumatology and orthopaedic services: seeking direction. <i>Rheumatology</i> , 2005, 44, 1332-1333.	0.9	3
129	Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 280-284.	0.5	30
130	Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. <i>Arthritis and Rheumatism</i> , 2003, 48, 46-53.	6.7	152
131	Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. <i>Rheumatology</i> , 2002, 41, 246-252.	0.9	30
132	The rheumatoid arthritis articular damage score: first steps in developing a clinical index of long term damage in RA. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 20-23.	0.5	27
133	Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. <i>Arthritis and Rheumatism</i> , 2002, 46, 906-912.	6.7	162
134	Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. <i>Arthritis and Rheumatism</i> , 2001, 44, 1033-1042.	6.7	77
135	Time to first occurrence of erosions in inflammatory polyarthritis: Results from a prospective community-based study. <i>Arthritis and Rheumatism</i> , 2001, 44, 1248-1253.	6.7	68
136	Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. <i>Clinical and Experimental Immunology</i> , 2000, 119, 182-188.	1.1	105
137	Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. <i>Rheumatology</i> , 2000, 39, 506-512.	0.9	79
138	Management of Acute Nontraumatic Upper Limb Ischemia. <i>Angiology</i> , 1999, 50, 715-720.	0.8	23
139	Erosive amyloidosis of the wrist and knee associated with oligoclonal bands. <i>Rheumatology</i> , 1997, 36, 494-497.	0.9	5
140	INCREASED NAILFOLD CAPILLARY DIMENSIONS IN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS. <i>Rheumatology</i> , 1996, 35, 1127-1131.	0.9	57